

**Table 2.** Comparison between baseline and end of study blood metabolites and markers of hepatic fatty acid synthesis and partitioning in non-diabetic participants stratified by change in erythrocyte DHA enrichment ( $\geq 2\%$  or  $< 2\%$ ).

	<b>DHA <math>\geq 2\%</math> (n=9)</b>		<b>DHA <math>&lt; 2\%</math> (n=7)</b>	
	<b>Baseline</b>	<b>End</b>	<b>Baseline</b>	<b>End</b>
<i><u>Fasting plasma concentrations</u></i>				
Glucose (mmol/L)	5.6 $\pm$ 0.2	5.9 $\pm$ 0.3	5.6 $\pm$ 0.2	5.5 $\pm$ 0.2
Insulin (mU/L)	35 $\pm$ 6	33 $\pm$ 8	40 $\pm$ 11	21 $\pm$ 3
Total cholesterol (mmol/L)	4.5 $\pm$ 0.3	4.7 $\pm$ 0.4	5.1 $\pm$ 0.6	4.6 $\pm$ 0.3
HDL-cholesterol (mmol/L)	1.2 (0.7, 1.4)	1.3 (0.9, 1.4)	1.0 (0.9, 1.2)	1.1 (1.0, 1.1)
LDL-cholesterol (mmol/L)	2.6 $\pm$ 0.2	3.0 $\pm$ 0.3	2.5 $\pm$ 0.3	2.5 $\pm$ 0.4
TG (mmol/L)	2.1 $\pm$ 0.3	1.5 $\pm$ 0.2**	2.3 $\pm$ 0.4	2.6 $\pm$ 0.5
VLDL-TG ( $\mu$ mol/L)	1348 $\pm$ 212	635 $\pm$ 88**	1497 $\pm$ 319	1641 $\pm$ 429
NEFA ( $\mu$ mol/L)	550 $\pm$ 55	570 $\pm$ 74	653 $\pm$ 79	663 $\pm$ 80
3OHB ( $\mu$ mol/L)	83 $\pm$ 13	58 $\pm$ 15	93 $\pm$ 19	106 $\pm$ 34
<i><u>Fasting contribution of hepatic DNL to VLDL-TG</u></i>				
Hepatic DNL (%)	14.8 $\pm$ 3.6	15.8 $\pm$ 2.2	11.1 $\pm$ 1.9	16.1 $\pm$ 2.4
VLDL TG derived from DNL ( $\mu$ mol/L)	61.0 $\pm$ 14	31.0 $\pm$ 6.0*	51.2 $\pm$ 14.5	84.1 $\pm$ 30.5
<i><u>Time-averaged postprandial plasma concentrations</u></i>				

Glucose (mmol/L)	6.2 ± 0.4	6.5 ± 0.4	6.1 ± 0.4	6.1 ± 0.2
Insulin (mU/L)	94 ± 15	88 ± 19	107 ± 33	67 ± 11
TG (mmol/L)	2.4 ± 0.3	1.8 ± 0.2 <sup>***</sup>	2.7 ± 0.4	2.9 ± 0.6
NEFA (μmol/L)	373 ± 47	368 ± 50	389 ± 55	382 ± 42
3OHB (μmol/L)	68 ± 10	46 ± 8 <sup>*</sup>	76 ± 17	69 ± 18
Chylomicron-TG (μmol/L)	180 ± 49	149 ± 37	268 ± 121	350 ± 158
VLDL-TG (mmol/L)	1.5 ± 0.2	0.8 ± 0.1 <sup>***</sup>	1.9 ± 0.3	1.7 ± 0.4

Time-averaged postprandial plasma and breath <sup>13</sup>C concentrations

[ <sup>13</sup> C]Chylomicron-TG (μmol/L)	0.6 ± 0.2	0.4 ± 0.1	1.0 ± 0.6	1.0 ± 0.6
[ <sup>13</sup> C]NEFA (μmol/L)	0.22 ± 0.09	0.20 ± 0.08	0.16 ± 0.05	0.07 ± 0.02 <sup>*</sup>
[ <sup>13</sup> C]VLDL-TG (μmol/L)	0.6 ± 0.1	0.3 ± 0.1 <sup>*</sup>	0.6 ± 0.2	0.7 ± 0.2
[ <sup>13</sup> C]3OHB (μmol/L)	0.1 ± 0.1	0.6 ± 0.2 <sup>*</sup>	0.2 ± 0.1	0.2 ± 0.1

---

Data presented as mean ± SEM

Abbreviations: End, end of study; HDL, high density lipoprotein; LDL, low density lipoprotein; TG, triglyceride; NEFA, non-esterified fatty acid; 3OHB, 3-hydroxybutyrate; VLDL, very low density lipoprotein; FFM, fat free mass

\*P<0.05; \*\*P<0.01; \*\*\*P<0.001 between baseline and end of study measurements within the respective groups